Qualitative

Our in-house healthcare moderators are highly recommended and referred within the industry by our clients & pharmaceutical companies. Carefully-selected fieldwork partners across Asia further extend our local reach. We have successfully completed projects with payors, KOLs, C-levels, physicians, co-medicals, caregivers and patients utilizing various methods such as in-field interviews (IDIs), telephone interviews (TDIs) & focus group interviews (FGDs) – as well as new innovative techniques.

Quantitative

We own proprietary panels in Japan, China & Korea with 115,000 HCPs opted in specifically for healthcare market research. We have completed 800+ online studies in Japan, China and Korea covering therapy areas such as Oncology, Endocrinology, Neurology, Gastroenterology, Collagen Diseases and many others.

Outcome Research

Real World Evidence studies:

Plamed Asia offers a complete solution for Real World Evidence studies by allowing you to interview HCPs and having HCPs refer patients to fill in patient self-completion sheets via both online and offline methods in various APAC countries.

PATIENT RECORD FORMS:

Plamed Asia offers a secure channel for you and your client to speak with HCPs directly about their patients’ treatment history and prescription history, while protecting both the HCP and patient’s identities. We collect patient and treatment information using both retrospective and prospective method.

Market Access

We connect you with the key decision makers and policy makers that can help you better understand the Regulatory, Market Access, Pricing, and Reimbursement environment in different countries in Asia. We utilize our existing payor network as well as custom recruiting appropriate respondents that can best fit your research objectives. At a glance, we have successfully recruited below respondents in our previous studies:

  • Korea: KECIP (Korea Expert Committee on Immunization Practices), KAAP (Korean Association for AIDs Prevention)

  • Taiwan: CDC (Critical Disease Control), NVF (National Vaccine Fund), National Health Insurance Administration (MOHW)

  • Japan: Vaccine Policy Committee, local government policy makers

  • Australia: Immunization Coalition, Ex-Australian Technical Advisory Group on Immunization (ATAGI)

  • China: National Medical Products Administration (NMPA), MOHRSS (Ministry of Human Resources and Social Security of the People's Republic of China).

  • Hong Kong: Payors - Current HA committee member; Chief Hospital Pharmacist (public)

MedTech/Medical Device

Medical Device studies:

MedTech has been one of the key focuses for Plamed Asia over the years. Not only do we have the capability of targeting different stakeholders for recruitment including end users, decision makers and laboratory personnel, but our moderators are also well trained in different specialty terminologies and are experienced in interviewing various stakeholders. Some of the device modalities we have include pacemakers, capnography devices, left bundle branch pacing (LBBP/LBBAP) devices, arterial catheters, CT injectors, laser cataract surgery devices, tissue diagnostic devices, ostomy and wound care devices / materials, haemodialysis and peritoneal dialysis devices, genomic testing devices, and more.